Navigation Links
Therapeutic Cells Derived From Reprogrammed (iPS) Stem Cells Display Early Aging
Date:2/10/2010

WORCESTER, Mass., Feb. 11 /PRNewswire-FirstCall/ -- Advanced Cell Technology, Inc. (OTCBB: ACTC) reported that a range of therapeutic cell types obtained from induced pluripotent stem (iPS) cells exhibit abnormal expansion and early cellular aging.  The research, which appears online (published-ahead-of- print) in the journal STEM CELLS by ACT and its collaborators at Stem International (SCRMI), Harvard Medical School, and the University of Illinois, compares a variety of replacement cell types derived from human iPS cells to their embryonic stem (ES) cell counterparts. 

The research shows that human iPS cells can generate blood, vascular and retinal cells with characteristics similar to those derived from ES cells, but with a dramatic decreased efficiency.  However, in distinct contrast to the ES cell derivatives, major differences were observed in cells derived from iPS cells, including significantly increased cell death (apoptosis), severely limited growth and expansion capability, as well as a substantially decreased capacity to generate blood progenitors.  After further differentiation into red blood cells, over a thousand-fold difference in expansion capability was observed in iPS cells versus ES cell progenitors.  Although vascular cells derived from iPS cells were capable of forming capillary-like structures, the cells also demonstrated early cell aging (senescence). Similarly, retinal cells derived from iPS cells also displayed early signs of aging.  

"Before clinical application, it will be necessary to determine the cause and extent of such abnormalities, and whether they also occur in stem cells generated using different reprogramming methods" said Robert Lanza, M.D., Chief Scientific Officer at ACT, and senior author of t
'/>"/>

SOURCE Advanced Cell Technology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. United Therapeutics Corporation to Announce Fourth Quarter and Annual 2009 Financial Results Before Market Open on Tuesday, February 16, 2010
2. Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents
3. Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board
4. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
5. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
6. Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation
7. The Honorable Tommy G. Thompson Joins the United Therapeutics Corporation Board of Directors
8. Cell Therapeutics Commits to PhRMAs Code on Interactions With Healthcare Professionals
9. WellGen, Inc. and RFI Ingredients to Collaborate on Therapeutic Nutrition Opportunities
10. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
11. Dennis Winger Joins Nektar Therapeutics Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 Cytokinetics, ... forces on February 28 with patients and health care ... awareness for Rare Disease Day®. Rare Disease Day ... and calling attention to the special challenges faced by ... them. , “Cytokinetics is proud to stand alongside patients ...
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
(Date:2/26/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... commercializes proprietary technologies and products for advanced microarray diagnostics, ... fiscal first quarter ended December  31, 2014. All figures ... unless otherwise stated. "During the quarter ... existing customers and add to our sales pipeline," said ...
(Date:2/26/2015)... Feb. 26, 2015 Protiviti ( www.protiviti.com ), ... of the Governance Portal , designed to increase ... compliance (GRC) tasks across multiple business units and projects. ... help customers better align their controls with the COSO ... ) requirements. In response to client feedback, Protiviti has ...
Breaking Biology Technology:Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3
... NeoStem Shareholders, We would like to take a ... for NeoStem (NYSE Amex: NBS ) – and to ... the company forward in 2012 and beyond. , We have ... LLC ("Amorcyte"). , We believe our therapeutic product development team ...
... LA JOLLA, Calif., Jan. 2, 2012 Renowned biochemist ... and CEO of The Scripps Research Institute January 1, ... for more than two decades. (Photo:  ... opportunity to advance the institute,s mission, creating knowledge in ...
... Dec. 28, 2011  MiMedx Group, Inc. (OTCBB: MDXG), ... protected regenerative biomaterials and bioimplants processed from human ... private placement offering to sell convertible notes and ... the offering, which commenced on October 15, 2011, ...
Cached Biology Technology:NeoStem's CEO Letter to Shareholders 2NeoStem's CEO Letter to Shareholders 3NeoStem's CEO Letter to Shareholders 4Michael A. Marletta Takes Office as New President of Scripps Research Institute 2MiMedx Group Completes $5,000,000 Private Placement 2MiMedx Group Completes $5,000,000 Private Placement 3
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , a ... today announced that Murali Prahalad , Ph.D., president and ... World Conference (PMWC) 2015: Silicon Valley, which is taking ... View, Calif. on January 26-28, 2015. ... of Age as Biomarkers." Last year, Epic Sciences was a ...
(Date:2/5/2015)... 2015 New Market Research Reports ... Forecasts To 2020 has Been Added to GrandViewReseach.com Report ... expected to reach USD 5.10 billion by 2020, according ... IR cameras help identify the site of tissue damage ... surging demand in medical imaging applications. They have been ...
(Date:2/5/2015)... 30, 2015  It is gratifying to see that ... for genomic science as a means to better understand ... treatment.  I was honored to participate in today,s White ... program. Since the 1980s my teams ... the first sequenced genome of a free living organism, ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2
... multisite trial designed to examine the safety and ... prevent HIV infection has opened to volunteer enrollment. ... Allergy and Infectious Diseases (NIAID), part of the ... various research institutions in Africa and the United ...
... Immunotherapeutics, has announced,the development of a new method ... at the base of the neck) works and ... in HIV-infected individuals. The,team of investigators led by ... at the CHUM Research Centre, and,Scientific Director and ...
... they see colors when viewing letters and numbers really ... of the University of California San Diego, have found. ... brains reveals that they show activation of color-perception areas. ... the hypothesis that the condition is due to cross-activation ...
Cached Biology News:International trial of two microbicides begins 2New insight into people who 'see' colors in letters and numbers 2
Rat Normal Multiple Tissue Array 1 slide...
EPH electrode, anode, 1. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
GENOMIPHI HY KIT 1000 RXN, 1 EA. Category: Genomics DNA Amplification....
... SlowFade Light Antifade Kit is an aqueous-based ... with fluorescent dyes. This formulation of antifade ... and Cascade Blue fluorophores that is often ... kit is available with the blue-fluorescent nucleic ...
Biology Products: